Late cardiotoxic effects of anthracycline chemotherapy in childhood malignancies

Journal of the Pakistan Medical Association

Volumn 58, Issue 12, 2008, Pages 683-687

  Roodpeyma, Shahla ^a   Moussavi, Farideh ^a   Kamali, Zinat ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM EXAMINATION; CHILD; CHILDHOOD CANCER; CONTROL GROUP; CONTROLLED STUDY; DIASTOLE; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GENDER; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; SCHOOL CHILD; SYSTOLE; SYSTOLIC DYSFUNCTION; TREATMENT DURATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOTOXINS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DIASTOLE; FEMALE; HEART VENTRICLES; HUMANS; INCIDENCE; IRAN; MALE; NEOPLASMS; PROSPECTIVE STUDIES; STATISTICS AS TOPIC; SURVIVORS; SYSTOLE; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 57449092923     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bleyer WA. The impact of childhood cancer on the United States and the world. CA Cancer J Clin 1990; 40:355-67.
2. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125:47-58.
3. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review .Ann Oncol 2002; 13:819-29.
4. Iarussi D, Pisacance C, Indolfi P, Casale F, Martino V, Di Tullio MT. Evaluation of left ventricular function in long - term survivors of childhood Hodgkin disease. Pediatr Blood Cancer 2005; 45:700-5.
5. Elbl L, Hrstkova H, Cbaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr 2003; 162:690-6.
6. Bu' Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms and pathophysiology. Br Heart J 1995; 73:340-50.
7. Lipshultz SE, Lipsitz SR ,Sallan SE, Dalton VM, Mone SM, Gelber RD et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23:2629-36.
8. Lipshultz SE. Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332:1738-44.
9. Godoy LY, Fukushige J, Igarashi H, Matsuzaki A, Ueda K. Anthracycline induced cardiotoxicity in children with malignancies. Acta Paediatr Jpn 1997; 39:188-93.
10. Monta R, Saxena A, Jain Y, Gupta S, Thavaraj V, Narain S et al. Anthracycline associated cardiac toxicity in children with malignancies. Indian Pediatr 2002; 39:549-55.
11. Agarwala S, Kumar R, Bhatnagar V, Bajpai M, Gupta DK, Mitra DK. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radio nuclide cardiac angiography. J Pediatr Surg 2000; 35:1786-9.
12. Suter TM. Meier B. Detection of Anthracycline induced cardiotoxicity: is there light at the end of tunnel? Ann Oncol 2002; 13:647-9.
13. Schmitt K, Tulzer G, Merl M, Aichhora G, Grillenberger A, Wiesinger G, et al. Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters. Eur J Pediatr 1995; 154:201-4.
14. Elbl L, Hrstkova H, Chaloupka V, Novotny J, Michalek J. The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography. Neoplasms 2003:50:191-7.
15. Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress echocardiography. Eur J Pediatr 2001; 160:607-10.
16. Lang D, Hilger F, Binswanger J, Andelfinger G, Hartmann W. Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress. Eur J Pediatr 1995; 154:340-5.
17. Sung RY, Haung GY, Shing MK, Oppenheimer SJ, Li CK, Lau J et al. Echocardiographic evaluation of cardiac function in pediatric oncology patients treated with or without anthracycline. Int J Cardiol 1997; 60: 239-48.
18. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995; 24:352-61.
19. Tjeerdsma G, Meinardi MT, van Der Graaf WT, van Den Berg MP, Mulder NH, Crijns HJ, et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999; 81:419-23.
20. Iarussi D, Galderisi M, Ratti G, Tedesco MA, Indolfi P, Casale F, et al. Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. Clin Cardiol 2001; 24:663-9.
21. Kismet E, Varan A, Ayabakan C, Alehan D, Portakal O, Buyukpamukcu M. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004; 42:220-4.
22. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin- induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001; 37:4-9.